Can-Fite BioPharma (CANF) C-level Sitdown summary

Clinical development pipeline

• Two drugs in clinical development: Namodenoson (liver/oncology) and Piclidenoson (psoriasis, rare diseases, veterinary use).

• Namodenoson is in phase III for advanced liver cancer, phase IIa for pancreatic cancer, and phase IIb for MASH.

• Piclidenoson is preparing for pivotal phase III in psoriasis and phase II in Lowe syndrome; also licensed for canine osteoarthritis.

Clinical trial progress and regulatory milestones

• Piclidenoson met primary and secondary endpoints (PASI 75, PGA) in phase III psoriasis trials.

• Pivotal phase III studies for psoriasis and liver cancer are ready, with regulatory alignment from FDA and EMA.

• Initiation of pivotal studies for pancreatic cancer and psoriasis, and licensing for canine osteoarthritis expected in 2024.

• Interim analysis of phase III liver cancer study and initiation of Lowe syndrome study planned for next year.

Financial and partnership highlights

• $20 million received in upfront and milestone payments from licensing deals.

• Potential for $130 million in future milestone payments and double-digit royalties on sales.

• Monetization strategy focuses on corporate partnerships and licensing agreements.